This condition often results from rough handling during mixing
The reason for the different mechanism of action is unknown but may relate to the difference in velocity of blood flow in arteries and veins
No therapeutic or diagnostic use is implied or authorized
Individuals with kidney disease, certain cancers, or high blood pressure should consult their physician before use
In preclinical research environments, the individual components of REGENO Cartalax + TB-500 + BPC-157 have been studied for their interaction with nitric oxide-associated pathways, angiogenic signaling networks, cytoskeletal organization mechanisms, extracellular matrix-associated processes, and chondrocyte-related signaling systems
No source presents a clinically validated injectable dose